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Background:Monoclonal antibodies against epidermal growth factor receptor (EGFR) have proved beneficial for the treatment
of metastatic colorectal cancer (mCRC), particularly when combined with predictive biomarkers of response. International
guidelines recommend anti-EGFR therapy only for RAS (NRAS, KRAS) wild-type tumors because tumors with RAS mutations
are unlikely to benefit.
Objectives: We aimed to review the cost-effectiveness of RAS testing in mCRC patients before anti-EGFR therapy and to assess
how well economic evaluations adhere to guidelines.
Methods: A systematic review of full economic evaluations comparing RAS testing with no testing was performed for articles
published in English between 2000 and 2018. Study quality was assessed using the Quality of Health Economic Studies scale,
and the British Medical Journal and the Philips checklists.
Results: Six economic evaluations (2 cost-effectiveness analyses, 2 cost-utility analyses, and 2 combined cost-effectiveness
and cost-utility analyses) were included. All studies were of good quality and adopted the perspective of the healthcare
system/payer; accordingly, only direct medical costs were considered. Four studies presented testing strategies with a
favorable incremental cost-effectiveness ratio under the National Institute for Clinical Excellence (£20 000-£30 000/QALY)
and the US ($50 000-$100 000/QALY) thresholds.
Conclusions: Testing mCRC patients for RAS status and administering EGFR inhibitors only to patients with RAS wild-type
tumors is a more cost-effective strategy than treating all patients without testing. The treatment of mCRC is becoming
more personalized, which is essential to avoid inappropriate therapy and unnecessarily high healthcare costs. Future
economic assessments should take into account other parameters that reflect the real world (eg, NRAS mutation analysis,
toxicity of biological agents, genetic test sensitivity and specificity).
Keywords: anti-EGFR, colorectal cancer, cost-effectiveness, pharmacogenetic tests, RAS, systematic review.
VALUE HEALTH. 2020; 23(1):114–126Introduction Advances in the treatment of metastatic colorectal cancerColorectal cancer (CRC) is a significant healthcare issue
worldwide. According to the global cancer statistics, CRC is the
third most commonly diagnosed cancer, with more than 1 million
new cases in 2018, and the second most common cause of cancer-
related mortality in both sexes combined.1,2 It is expected that the
incidence of CRC will increase in the Western world owing to
aging populations and poor lifestyles.3 At diagnosis, about 25% of
patients have metastases that have already developed, and almost
50% of all CRC patients will form metastases as the disease
progresses.4ss correspondence to: Brigid Unim, MD, PhD, Department of Public Health an
taly. Email: brigid.unim@uniroma1.it
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doi.org/10.1016/j.jval.2019.07.009(mCRC) have been made in recent years and mainly consist of the
introduction of monoclonal antibodies against epidermal growth
factor receptor (EGFR) or vascular endothelial growth factor
(VEGF) in addition to chemotherapy. The mechanisms of action of
monoclonal antibodies include interference with DNA replication
and inhibition of EGFR activity (eg, cetuximab, panitumumab) or
VEGF (eg, bevacizumab).5 Nevertheless, treatment of mCRC pa-
tients with anti-EGFR antibodies is effective only for tumors
lacking mutations in RAS genes (mainly KRAS and NRAS).6-8 KRAS
mutations are detected in about 40% of CRCs4; the frequency of
NRAS mutations ranges between 1% and 7%, whereas almost nod Infectious Diseases, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185
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SYSTEMATIC LITERATURE REVIEW 115HRAS mutations are seen in CRCs.9 There are no validated pre-
dictive markers available for anti-VEGF therapy.4
International guidelines for CRC recommend testing the
mutation status of both KRAS and NRAS. Anti-EGFR therapy
should be given only when no mutations exist in these genes (ie,
KRAS and NRAS are wild-type). Routine testing for other muta-
tion profiles in clinical practice (eg, BRAF, EGFR, PI3K and PTEN
status) is not recommended in these patients because it is not
necessary for therapeutic decision making. Nevertheless, it
provides information for identifying subgroups and stratifying
patients in clinical trials.5,10,11 In particular, BRAF testing is rec-
ommended in mCRC patients as a prognostic marker.10 Given the
importance of personalized treatment of CRC, the aims of the
study are (1) to review and evaluate the evidence supporting the
cost-effectiveness of genetic testing of mCRC patients for RAS
mutations before targeted therapy with monoclonal antibodies
in all treatment lines and (2) to evaluate how well economic
evaluations adhere to guidelines on RAS testing in mCRC
patients.
Methods
Literature Search and Study Selection
This systematic review of economic evaluations of RAS testing
in patients with mCRC was conducted according to the guidelines
from the Centre for Reviews and Dissemination, University of
York, on undertaking systematic reviews of economic evalua-
tions12 and the Cochrane Handbook for systematic reviews.13 Two
investigators independently searched Medline, the Health Tech-
nology Assessment Database, the National Health Service Eco-
nomic Evaluation Database, Scopus, and Web of Science. The
search was limited to English-language records published be-
tween January 2000 and December 2018. The following search
terms were used: genetic* OR pharmacogenetic* economic eval-
uation*, cost-effectiveness, cost-utility, cost-benefit, cost-minimi-
zation, OR QALY* OR LYG* AND colorectal cancer*. The search
strings were adjusted for each database while maintaining a
common overall architecture. Titles, abstracts, and full texts of the
identified records were assessed, and discrepancies were resolved
by consensus. We excluded studies that compared only the effi-
cacy or effectiveness of various anti-EGFR treatments and those
that focused on adverse events associated with anti-EGFR treat-
ment (eg, treatment of neutropenia guided by UGT1A1 genetic
testing; Appendix 1 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2019.07.009). A manual review of refer-
ences from eligible economic analyses was also performed to
identify potentially relevant studies. The records were selected
according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) Statement.14 We have applied the
methodological approach used in this review in previous
studies.15-18
Data Extraction and Quality Assessment
Two reviewers independently extracted data and assessed
the quality of the studies using the Quality of Health Economic
Studies (QHES) scale19 and the British Medical Journal20 and Phi-
lips checklists.21 To compare monetary values expressed in
different currencies and for different years, we used the national
inflation rates provided by the World Bank22 to express the costs
of genetic testing in national currencies in 2017. These values were
then converted to 2017 international USD (Int$) using purchasing
power parity exchange rates.23 We performed a descriptiveanalysis of the included studies to summarize their main charac-
teristics and to compare study interventions, methods, results, and
adherence to guidelines.
Results
The literature search yielded 163 records, of which 116 were
excluded after screening by title and abstract. Twenty-five records
were excluded after reviewing the full text, leaving 6 economic
evaluations for inclusion in the review (Fig. 1).24-29
General Characteristics of the Studies
The 6 studies were published between 2010 and 2017 (Table 1)
and conducted in the United Statesl,25,26 Germany,26
Switzerland,27 Canada,28and Japan.24,29 The types of economic
evaluation used were cost-effectiveness analysis,25,26 cost-utility
analysis (CUA),28,29 or both cost-effectiveness analysis and
CUA.24,29 In all studies, a comparison was made between testing
for RAS mutation status before treatment and a no-testing strat-
egy. The viewpoint in all studies was that of the healthcare system
or healthcare payer, and therefore only direct medical costs were
included in the analysis. All studies used a Markov model to es-
timate cost-effectiveness, which was reported as incremental
cost-effectiveness ratio (ICER), life-year(s) gained (LYG), and
quality-adjusted life-year(s) (QALY). The most frequently used
discount rate for costs and benefits was 3%.25,27,29 The ICER
thresholds reported in the studies were in the range of $50 000 to
$100 000,25,27,29 U5 million to U6 million,24,29 and £20 000 to £30
000.27,29
Basic Assumptions and Quality of the Studies
All studies specified the genotype prevalence, except one,28
and the KRAS wild-type was more common. Two studies re-
ported the genetic test sensitivity and specificity,26,27 which
ranged between 95% and 100%. All studies also reported the cost of
genetic testing and the relative currency; the cost of RAS testing
ranged from Int $177 to Int $317. Combined KRAS and BRAF testing
cost approximately Int $323, whereas comprehensive next-
generation sequencing (NGS) profiling cost Int $4016 (Table 1).
Saito et al24 and the Ontario Ministry of Health28 also considered
severe adverse events (grades 3 and 4) in the economic model.
Regarding methodological quality, the results of the QHES scale
(Table 2) were consistent with the BMJ findings. The studies are of
high quality, with the lowest score of 84 awarded to Vijayaraghavan
et al.26 The studies, except one,25 reported the perspective of the
analysis (item1). Uncertainty in the economicmodelswas correctly
handled by probabilistic sensitivity analysis (PSA)27-29 andmultiple
1-way24,25 and 2-way sensitivity analyses24 (item 5). Vijayar-
aghavan et al26 conducted only a 1-way sensitivity analysis; in
addition, benefits and costs were not discounted (item 8). Blank
et al27 did not report the price data (item 9). The OntarioMinistry of
Health28 study did not discuss its results (item 13), whereas Saito
et al24 did not disclose the source of funding for the study (item
16).21 Most structural issues (Table 3) were observed in sections
S125-27,29 and S725-29 of the Philips checklist.21 Most data issues
regarded sections D1,24-29 D2,25,26,28,29 and D4.24-29 The model was
calibrated (C1) in one study.25
Adherence to Guidelines
International guidelines5,10,11,30 recommend that RAS screening
should include KRAS and NRAS analysis as predictors of response
to anti-EGFR antibodies, but none of the economic evaluations
Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram of study selection process.
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116 VALUE IN HEALTH JANUARY 2020included in this review took NRAS mutation status into consider-
ation. In the study by Saito et al,24 KRAS testing correctly guided
the first-line treatment regimen with panitumumab, but the
comprehensive screening strategy included not recommended
genes as predictors of anti-EGFR response (ie, PTEN, ERBB2, SRC,
BRAF, and RNF43).5,10,11,30 Furthermore, Behl et al25 and Blank
et al27 used BRAF genetic testing to guide the therapy of mCRC
patients with cetuximab, which is not recommended because the
BRAF test is a prognostic marker and thus cannot predict the
response to anti-EGFR antibodies.5,10,11,30
Anti-EGFR therapy as the first-line treatment of RAS wild-type
mCRC patients is recommended unless contraindicated (by, for
example, reduced organ function or cardiovascular insuffi-
ciency).10,11,31 Nonetheless, only Saito et al24 included first-line
therapy in the economic model. The Ontario Ministry of Health
study28 adhered to the use of anti-EGFR agents specifically inthird-line treatment as recommended by the Canadian Expert
Group.32
Cost-Effective Strategies
In all 6 studies, the comparative cost-effectiveness analyses
focused on the benefit of anti-EGFR therapy guided by genetic
testing rather than on the benefit of anti-EGFR antibodies alone.
Anti-EGFR antibodies were provided to mCRC patients in first-
line24 or subsequent lines25-29 as monotherapy25,27-29 or combi-
nation therapies.24,26,28 The latter consisted of monoclonal
antibodies together with irinotecan,28 FOLFIRI (irinotecan,
5-fluorouracil, and leucovorin),24,26 or FOLFOX (leucovorin,
5-fluorouracil, and oxaliplatin)24; the chemotherapy components
were administered by infusion (irinotecan, leucovorin, oxaliplatin,
5-fluorouracil) or bolus (5-fluorouracil).
Table 1. General characteristics of full economic evaluations of RAS genetic testing.
First
author,
country,
year
Type of
economic
evaluation
Time
horizon
Perspective Model
of
analysis
Sensitivity
analysis
Discount
rate, %
Source of
effectiveness
data
Source
of cost
Cost
of testing
Cost
of testing
in Int
$ (2017)
Source of
funding
Saito, Japan,
201724
CEA, CUA 5 years Healthcare
payer
Markov
model
One way;
multivariate
2 (cost
and
benefits)
RCT;
retrospective
analysis;
meta-analysis
Official
tariff
RAS testing:
U25.000;
comprehensive
screening:
U400.000
RAS testing:
251;
comprehensive
screening: 4016
Missing
Behl, USA,
201225
CEA 10 years Missing Markov
model
One way 3 (cost
and
benefits)
RCT Health
insurance
plan
KRAS testing:
US $224;
KRAS 1 BRAF
testing:
US $303
KRAS testing:
239; KRAS 1
BRAF testing:
323
National
Cancer
Institute at
the National
Institutes of
Health, USA
Vijayaraghavan,
Germany and
USA, 201226
CEA Lifetime Healthcare
payer
Markov
model
One way Missing RCT;
retrospective
analysis
USA:
health
insurance
plan;
Germany:
literature,
expert
opinion
KRAS test:
US $243
259 Roche
Molecular
Systems, Inc,
Pleasanton,
CA, USA
Blank,
Switzerland,
201127
CUA Lifetime Healthcare
system
Markov
model
One way;
scenario;
probabilistic
3 (cost
and
benefits)
RCT Official
tariff
V394 per
analysis
317 Educational
grant of the
ETH, Zurich
Foundation,
and the
Competence
Center for
Systems
Physiology
and Metabolic
Diseases,
Zurich,
Switzerland
The Ontario
Ministry of
Health and
Long-Term
Care, Canada,
201028
CUA Lifetime Ontario
Ministry of
Health and
Long-Term
Care
Markov
model
Probabilistic 5 (cost
and
benefits)
RCT Literature;
health
insurance
plan;
public
database
KRAS testing:
Can $500
448 Ontario
Ministry of
Health and
Long-Term
Care, Toronto,
Ontario,
Canada
Shiroiwa,
Japan, 201029
CEA, CUA 2.5
years
Healthcare
payer
Markov
model
One way;
probabilistic
3 (cost
and
benefits)
RCT Social
insurance
plan;
official
drug tariff
KRAS test:
U20.000
(US $220)
247 Roche
Diagnostics
K.K., Tokyo,
Japan
CEA indicates cost-effectiveness analysis; CUA, cost-utility analysis; RCT, randomized clinical trial; Int$ 2017, international US dollars; U, Japanese yen.
SYSTEMATIC LITERATURE REVIEW 117RAS testing followed by cetuximab mono- or
combination therapy
In the article by Vijayaraghavan et al26 (Table 4), using KRAS
testing to select patients for cetuximab monotherapy is a domi-
nant strategy with equal effectiveness and lower costs; it can save
$8040/patient in the United States and V3856/patient in Germany.
Administering cetuximab together with irinotecan to KRAS wild-
type patients and irinotecan alone to patients with KRAS muta-
tions increased life expectancy at an additional cost of $35 539/
LYG. In Switzerland,27 testing for KRAS and BRAF status followed
by cetuximab treatment if no mutations were detected was the
most cost-effective approach, with an ICER of V62 653/QALY when
compared with the reference strategy (best supportive care [BSC]
for all, no testing, no cetuximab). The utilities were derived from
the CO.17 trial in which the Health Utility Index Mark 3 scores
were prospectively collected. A value of 0.71 was applied33 to
wild-type and mutant patients in the stable state without cetux-
imab treatment and to mutant patients receiving cetuximab; a
value of 0.5 was applied34,35 to patients in the progression state. In
the Canadian setting,28 KRAS testing was cost-effective for cetux-
imab monotherapy at a willingness-to-pay (WTP) value of $54 802and for cetuximab with irinotecan combination therapy at a WTP
value of $42 701. The latter was the preferred cost-effective option
when all treatment strategies were considered simultaneously in
the analysis. The utility value of 0.71 was applied to all patients; an
increase of 0.07 for cetuximab, panitumumab, or cetuximab with
irinotecan treatments was assigned to patients for all strategies
except BSC.33 In a sensitivity analysis,36 the utility increase for
panitumumab was estimated at 0.12
Two studies found high ICERs for RAS testing followed by anti-
EGFR therapy (Table 4).25,29 According to Behl et al,25 screening for
KRAS and BRAF improves the cost-effectiveness of anti-EGFR
therapy in the United States, although the ICER, compared with
the reference strategy (no anti-EGFR therapy), remains above the
US threshold of $100 000/QALY. In the analysis by Shiroiwa et al,29
the KRAS-testing strategy (KRAS testing plus cetuximab for pa-
tients with wild-type KRAS) was dominant compared with the no–
KRAS-testing strategy (cetuximab to all patients without KRAS
testing) with a cost reduction of U0.5 million/patient. Neverthe-
less, the ICER of cetuximab (with or without a KRAS test) fell above
the Japanese, American, and British thresholds, even if treatment
was limited to patients with wild-type KRAS. The utilities for wild-
Table 2. Quality of full economic evaluations of RAS genetic testing.
Item Points Saito,
201724
Behl
201225
Vijayaraghavan,
201226
Blank,
201127
The Ontario
Ministry of
Health,
201028
Shiroiwa,
201029
1. Was the study objective presented in a clear,
specific, and measurable manner?
7 x x x x x x
2. Were the perspective of the analysis
(societal, third-party payer, etc) and reasons
for its selection stated?
4 x — x x x x
3. Were variable estimates, from the best
available source, used in the analysis
(ie, randomized control trial; best, expert
opinion; worst)?
8 x x x x x x
4. If estimates came from a subgroup analysis,
were the groups prespecified at the beginning
of the study?
1 x x x x x x
5. Was uncertainty handled by (1) statistical
analysis to address random events or
(2) sensitivity analysis to cover a range
of assumptions?
9 x x — x x x
6. Was incremental analysis performed between
alternatives for resources and costs?
6 x x x x x x
7. Was the methodology for data abstraction
(including the value of health states and
other benefits) stated?
5 x x x x x x
8. Did the analytic horizon allow time for all
relevant and important outcomes? Were
benefits and costs that went beyond 1 year
discounted (3% to 5%) and justification
given for the discount rate?
7 x x — x x x
9. Was the measurement of costs appropriate
and the methodology for the estimation of
quantities and unit costs clearly described?
8 x x x — x x
10. Were the primary outcome measure(s)
for the economic evaluation clearly stated,
and did they include the major short-term,
long-term, and negative outcomes?
6 x x x x x x
11. Were the health outcome measures/scales
valid and reliable? If previously tested, valid
and reliable measures were not available,
was justification given for the
measures/scales used?
7 x x x x x x
12. Were the economic model (including structure),
study methods and analysis, and the components of the
numerator and denominator displayed in a clear,
transparent manner?
8 x x x x x x
13. Were the choice of economic model, main
assumptions, and limitations of the study stated
and justified?
7 x x x x — x
14. Did the author(s) explicitly discuss direction
and magnitude of potential biases?
6 x x x x x x
15. Were the conclusions/recommendations of
the study justified and based on the study results?
8 x x x x x x
16. Was there a statement disclosing the source
of funding for the study?
3 — x x x x x
Total 100 97 96 84 92 93 100
118 VALUE IN HEALTH JANUARY 2020type KRAS patients receiving cetuximab and the ineffective/no
cetuximab group were assumed to be 0.7 for progression-free
survival (PFS).33 Disutility scores were altered by gamma distri-
bution in the PSA.RAS testing followed by panitumumab mono- or
combination therapy
Saito et al24 (Table 4) considered the administration of
panitumumab together with FOLFOX without genetic testing as
Table 3. Risk of bias assessment using the Philips checklist for economic modeling studies.
Quality criteria Questions for critical appraisal Saito,
201724
Behl
201225
Vijayaraghavan
201226
Blank,
201127
The Ontario
Ministry of
Health
201028
Shiroiwa,
201029
Structure (S)
S1: Statement
of decision
problem/objective
Is there a clear statement of the
decision problem?
U U U U U U
Is the objective of the evaluation and
model specified and consistent with
the stated decision problem?
U U U U U U
Is the primary decision maker specified? U __ __ __ U __
S2: Statement
of scope/
perspective
Is the perspective of the model
stated clearly?
U __ U U U U
Are the model inputs consistent with
the stated perspective?
U NA U U U U
Has the scope of the model been stated
and justified?
U U U U U U
Are the outcomes of the model consistent
with the perspective, scope and overall
objective of the model?
U U U U U U
S3: Rationale
for structure
Has the evidence regarding the model
structure been described?
U U U U U U
Is the structure of the model consistent
with a coherent theory of the health
condition under evaluation?
U U U U U U
Are the sources of data used to develop
the structure of the model specified?
U U U U U U
Are the causal relationships described by
the model structure justified appropriately?
U __ __ U U U
S4: Structural
assumptions
Are the structural assumptions transparent
and justified?
U __ __ U U U
Are the structural assumptions reasonable
given the overall objective, perspective
and scope of the model?
U U U U U U
S5: Strategies/
comparators
Is there a clear definition of the options
under evaluation?
U U U U U U
Have all feasible and practical options
been evaluated?
U U U U U U
Is there justification for the exclusion
of feasible options?
NA NA NA NA NA NA
S6: Model type Is the chosen model type appropriate given
the decision problem and specified causal
relationships within the model?
U U U U U U
S7: Time
horizon
Is the time horizon of the model sufficient
to reflect all important differences
between options?
U U U U U U
Is the time horizon of the model, the duration
of treatment and the duration of treatment
effect described and justified?
U __ __ __ __ __
S8: Disease
states/
pathways
Do the disease states (state transition model)
or the pathways (decision tree model) reflect
the underlying biological process of the disease
in question and the impact of interventions?
U U U U U U
S9: Cycle length Is the cycle length defined and justified in
terms of the natural history of disease?
U U __ U U U
Data (D)
D1: Data
identification
Are the data identification methods transparent
and appropriate given the objectives of the
model?
U U U U U U
continued on next page
SYSTEMATIC LITERATURE REVIEW 119
Table 3. Continued
Quality criteria Questions for critical appraisal Saito,
201724
Behl
201225
Vijayaraghavan
201226
Blank,
201127
The Ontario
Ministry of
Health
201028
Shiroiwa,
201029
Where choices have been made between data
sources, are these justified appropriately?
U NA NA __ __ NA
Has particular attention been paid to identifying
data for the important parameters in the model?
U U U U U U
Has the process of selecting key parameters
been justified and systematic methods used
to identify the most appropriate data?
__ U __ U U __
Has the quality of the data been assessed
appropriately?
__ __ __ __ __ __
Where expert opinion has been used, are
the methods described and justified?
__ NA __ NA __ NA
D2: Pre-model
data analysis
Are the pre-model data analysis methodology
based on justifiable statistical and epidemiological
techniques?
U __ __ U __ __
D2a: Baseline
data
Is the choice of baseline data described
and justified?
U U U U U U
Are transition probabilities calculated
appropriately?
U __ __ U __ __
Has a half cycle correction been applied to
both cost and outcome?
__ __ __ __ __ __
If not, has this omission been justified? __ __ __ __ __ __
D2b: Treatment
effects
If relative treatment effects have been derived
from trial data, have they been synthesized
using appropriate techniques?
__ __ __ __ __ __
Have the methods and assumptions used to
extrapolate short-term results to final outcomes
been documented and justified?
__ U __ __ __ __
Have alternative assumptions been explored
through sensitivity analysis?
U U U U U U
D2c: Quality-
of-life weights/
utilities
Are the utilities incorporated into the model
appropriate?
U NA NA U U U
Is the source for the utility weights referenced? U NA NA U U U
Are the methods of derivation for the utility
weights justified?
__ NA NA U U U
D3: Data
incorporation
Have all data incorporated into the model been
described and referenced in sufficient detail?
U U U U U U
Has the use of mutually inconsistent data been
justified (i.e. are assumptions and choices
appropriate)?
U NA __ U NA U
Is the process of data incorporation transparent? U U U U U U
If data have been incorporated as distributions,
has the choice of distribution for each parameter
been described and justified?
NA NA NA NA NA NA
If data have been incorporated as distributions,
is it clear that second order uncertainty is
reflected?
NA NA NA NA NA NA
D4: Assessment
of uncertainity
Have the four principal types of uncertainty
been addressed?
__ __ __ __ __ __
If not, has the omission of particular forms of
uncertainty been justified?
__ __ __ __ __ __
D4a:
Methodological
uncertainity
Have methodological uncertainties been
addressed by running alternative versions of
the model with different methodological
assumptions?
__ __ __ U __ U
continued on next page
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Table 3. Continued
Quality criteria Questions for critical appraisal Saito,
201724
Behl
201225
Vijayaraghavan
201226
Blank,
201127
The Ontario
Ministry of
Health
201028
Shiroiwa,
201029
D4b: structural
uncertainity
Is there evidence that structural uncertainties
have been addressed via sensitivity analysis?
__ __ __ __ __ __
D4c: Heterogeneity Has heterogeneity been dealt with by running
the model separately for different sub-groups?
__ __ __ __ __ __
D4d: Parameter Are the methods of assessment of parameter
uncertainty appropriate?
U U __ U U U
Has probabilistic sensitivity analysis been done,
if not has this been justified?
__ __ __ U U U
If data are incorporated as point estimates, are
the ranges used for sensitivity analysis stated
clearly and justified?
U U __ U U U
CONSISTENCY (C)
C1: Internal
consistency
Is there evidence that the mathematical logic of
the model has been tested thoroughly before
use?
__ U __ __ __ __
C2: External
consistency
Are the conclusions valid given the data
presented?
U U U U U U
Are any counterintuitive results from the model
explained and justified?
NA NA NA NA NA NA
If the model has been calibrated against
independent data, have any differences been
explained and justified?
NA U NA NA NA NA
Have the results of the model been compared
with those of previous models and any
differences in results explained?
U U U U __ U
SYSTEMATIC LITERATURE REVIEW 121first-line therapy, demonstrating that the no-testing strategy was
less effective because it saved fewer lives than comprehensive
screening (1.504 vs 1.706 LYG) or RAS testing (1.504 vs 1.631 LYG);
comprehensive screening was the costliest of the 3 strategies.
The utilities were measured with the EQ-5D instrument in a
previous study.37 The values of 0.821, 0.782, and 0.681 were
applied to patients receiving first-line therapy, second-line ther-
apy, and BSC, respectively. Disutilities related to adverse events
(0.02) were based on expert opinions.
Vijayaraghavan et al26 demonstrated that KRAS testing before
panitumumab monotherapy in subsequent lines of treatment
saved $7546/patient in the United States and V4612/patient in
Germany compared with administering panitumumab to all pa-
tients. In the Canadian setting,28 KRAS testing before pan-
itumumab monotherapy as third-line treatment was cost-effective
at a WTP value of Can $47 795.
Genome sequencing and RAS testing followed by
anti-VEGF combination therapy
According to Saito et al24 (Table 4), comprehensive molecular
profiling, using NGS technology, followed by the combination of
bevacizumab with FOLFOX in first-line or with FOLFIRI in second-
line treatment is a cost-effective strategy with an ICER of U4 260
187/QALY compared with RAS testing at the Japanese WTP value of
U6 million/QALY.Discussion
The importance of predictive genetic testing using RAS gene
mutation status before therapy with monoclonal antibodies hasbeen unequivocally demonstrated: clinical trials show that mCRC
patients with KRAS mutations do not respond to anti-EGFR ther-
apy,6,7 and the therapy may negatively affect PFS and overall
survival (OS).8,11 The present systematic review of full economic
evaluations highlights the cost-effectiveness of RAS testing before
anti-EGFR therapy for all lines of treatment. It also indicates that
RAS genetic testing before anti-EGFR therapy increases treatment
costs and has a considerable effect on the healthcare system from
the payer’s perspective; nonetheless, it is a cost-effective strategy
compared with anti-EGFR therapy without testing. With respect to
the National Institute for Clinical Excellence WTP threshold (£20
000-£30 000/QALY or LYG)38 and the US thresholds ($50 000-$100
000/QALY or LYG),39 4 studies adopted strategies with a favorable
ICER for KRAS or BRAF testing before anti-EGFR therapy.24,26-28
Behl et al25 and Shiroiwa et al29 reported ICERs that exceeded
these thresholds. The findings of Behl et al25 are less supportive of
the use of anti-EGFR therapy and indicate lower cost savings from
KRAS testing than other analyses. This could be due to the inclu-
sion of costs for the resection of metastases, recurrence after
resection, and conversion therapies in their study. The impact of
resection costs and subsequent therapies on the analysis is
indisputable, considering that almost 50% of patients in their
model have recurrence within a year of resection. Nevertheless,
accounting for these issues makes the model much closer to the
real world, even if the overall cost-effectiveness is less favorable.
The high ICERs found in the analysis by Shiroiwa et al29 were
mainly related to the cost of cetuximab in the Japanese setting;
none of the other parameters varied in the sensitivity analysis (eg,
cost of KRAS testing, KRAS mutation, cost of BSC) affected their
results substantially. In general, the sensitivity analyses of the
economic evaluations showed that ICERs were influenced by
Table 4. Treatment strategies and results of the cost-effectiveness analysis of RAS genetic testing in patients with metastatic colorectal
cancer.
First author,
country, year
Genes Treatment
lines/drugs
Reference
strategy
Testing and treatment
strategies
ICER Threshold/
conclusion
Saito, Japan,
201724
KRAS,
BRAF,
PTEN,
SRC,
ERBB2,
RNF43
First line:
panitumumab 1
FOLFOX
Second-line:
bevacizumab 1
FOLFIRI
Third-line: BSC
Missing (1) Anti-EGFR therapy without
screening (no testing)
(2) RAS mutation screening
before anti-EGFR therapy
(RAS screening)
(3) Comprehensive molecular
profiling before anti-EGFR
therapy (comprehensive
screening)
(2) vs (1): U3 049
132/QALY
(3) vs (2): U4 260
187/QALY
U6 million/ QALY
Comprehensive
screening was
more cost-effective
compared with RAS
screening
Behl, USA,
201225
KRAS,
BRAF
All lines
cetuximab 1
irinotecan
(1) No cetux
imab ther
apy (BSC)
(2) Screening for KRAS and BRAF
mutations 1 cetuximab
(after first-line chemotherapy)
(3) Screening for KRAS
mutations only 1 cetuximab
(after first-line chemotherapy)
(4) Anti-EGFR therapy without
testing (after first-line
chemotherapy)
(2) vs (1): $648
396/LYG
(3) vs (2): $2814
338/LYG
(4) vs (3): $2932
767/LYG
US $50 000 to
$100 000/QALY
Screening for KRAS
and BRAF mutation
improves cost-
effectiveness but
the ICER remains
above the threshold
Vijayaraghavan,
Germany and
USA, 201226
KRAS After first line,
cetuximab alone
or combined
(irinotecan/
FOLFIRI);
panitumumab
Missing (1.1) KRAS testing 1 combination
therapy: cetuximab 1
irinotecan/FOLFIRI if KRAS
wt 1 BSC if chemotherapy
fail AND cetuximab 1 BSC
OR panitumumab 1 BSC
if KRAS mutation
(1.2) KRAS testing 1 combination
therapy: cetuximab 1
irinotecan/FOLFIRI if KRAS
wt AND chemotherapy
without EGFR inhibitors/BSC
if KRAS mutation
(2) No KRAS testing 1
combination therapy
(3) KRAS testing 1 cetuximab
alone
(4) No KRAS testing 1 cetuximab
alone
(5) KRAS testing 1 panitumumab
alone
(6) No KRAS testing 1
panitumumab alone
(prior therapy includes
first-line FOLFOX or FOLFIRI
6 bevacizumab and/or
second-line therapy with
FOLFIRI/FOLFOX)
(1.2) vs (1.1): $35
539/LYG
(1.1) vs (2): Less
expensive,
less
effective
(2) vs (1.2): Higher
cost, same
effectiveness
(4) vs (3): Higher
cost, same
effectiveness
(6) vs (5): Higher
cost, same
effectiveness
Threshold not
reported.
Under most
scenarios,
KRAS testing saved
money with
equivalent
clinical outcomes
Blank,
Switzerland,
201127
KRAS,
BRAF
Last line,
cetuximab
(1) BSC for all
(no testing,
no
cetuximab)
(2) KRAS only: BRAF testing if
KRAS wt 1 cetuximab and
BSC if KRAS/BRAF wt; BSC if
KRAS/BRAF mutation; BSC if
KRAS wt/BRAF mutation
(3) KRAS 1 cetuximab and BSC if KRAS
wt; BSC if KRAS
mutation
(4) No testing strategy 1
cetuximab and BSC to the
entire patient population
(cetuximab is provided as
last-line therapy)
(2) vs (1): V62
653/QALY
(3) vs (2): V313
537/QALY
(4) vs (3): V314
588/QALY
V38 500–V77 000/
QALY (US $50 000
to $100 000)
Testing for KRAS
and
BRAF is the most
cost-
effective approach,
despite high costs
for predictive testing
continued on next page
122 VALUE IN HEALTH JANUARY 2020
Table 4. Continued
First author,
country, year
Genes Treatment
lines/drugs
Reference
strategy
Testing and treatment
strategies
ICER Threshold/
conclusion
The Ontario
Ministry of
Health and
Long-Term Care,
Canada, 201028
KRAS Third line
cetuximab alone
or combination
(irinotecan)/
panitumumab
Missing (0) BSC for all (no KRAS test;
no treatment)
(1a) KRAS test 1 cetuximab and
BSC for patients with KRAS
wt and BSC in patients with
KRAS mutations
(1b) No KRAS test 1 cetuximab
and BSC for all
(2a) KRAS test 1 panitumumab
and BSC for patients
with KRAS wt and BSC
in patients with KRAS mutations
(2b) No KRAS test 1
panitumumab and
BSC for all
(3a) KRAS test 1 cetuximab
and irinotecan and BSC for
patients with KRAS wt and
BSC in patients with KRAS
mutations
(3b) No KRAS test 1 cetuximab
and irinotecan and BSC
for all
(cetuximab, panitumumab,
cetuximab 1 irinotecan, or BSC are
provided as third-line therapy)
(1a) vs (0): $54
802/QALY
(1b) vs (1a):
dominated
(2a) vs (0): $47
795/QALY
(2b) vs (2a):
$308 236/
QALY
(3a) vs (0): $42
710/QALY
(3b) vs (3a):
$163 396/
QALY
Can $50 000/QALY
Strategies
considering
KRAS testing were
found to be cost-
effective when
compared with the
corresponding
strategies of no
KRAS testing
Shiroiwa, Japan,
201029
KRAS Last line,
cetuximab
Missing (1) KRAS testing strategy: KRAS
test 1 cetuximab as last
line-therapy if KRAS wt OR
BSC if KRAS mutation
(2) No-KRAS-testing strategy: no
test 1 cetuximab as
last-line
therapy for all patients
(3) No-cetuximab strategy: no
test 1 BSC for all patients
(1) vs (2):
dominant
(1) vs (3): U16
million/QALY
(2) vs (3): U21
million/QALY
Japan: U6 million/
QALY; UK: £20 000–
£30 000/QALY;
US: $50 000–$100
000/QALY
KRAS-testing
strategy
dominates no-KRAS-
testing strategy
(cost reduction
0.5 million per
patient);
however, the ICER of
cetuximab (with or
without KRAS test)
falls above the
thresholds
BSC indicates best supportive care; Can$, Canadian dollars; EGFR, epidermal growth factor receptor; FOLFOX, leucovorin, 5-fluorouracil, and oxaliplatin; FOLFIRI,
irinotecan, 5-fluorouracil, and leucovorin; ICER, incremental cost-effectiveness ratio; LYG, life per year gained; QALY, quality-adjusted life-year; wt, wild-type; U,
Japanese yen.
SYSTEMATIC LITERATURE REVIEW 123various parameters, such as utility value for progressive disease,27
cost of therapeutic regimens with anti-EGFR agents,26,28,29 cost of
BSC and KRAS wild-type prevalence,26 OS,28,29 PFS,24 and cost of
NGS sequencing.24
The evaluation of adherence of economic models to interna-
tional clinical guidelines highlighted different issues. First, Saito
et al24 included in their model other genes not recommended in
clinical guidelines as predictors of anti-EGFR response and did not
consider NRAS mutation status as required. They erroneously
concluded that comprehensive screening of these genes in mCRC
patients should be considered before monoclonal antibody ther-
apy. Nevertheless, this approach cannot be recommended for
introduction into clinical practice given that it is unnecessary and
incurs the high cost of NGS technologies (Int $4016; 13- to 23-fold
higher than KRAS testing). This conclusion does not imply that
NGS approaches have no place in clinical practice. NGS has many
advantages over Sanger sequencing, including its high speed and
improved accuracy and cost-effectiveness for the detection ofmultiple genetic alterations with a minimum amount of DNA.
Indeed, one clinical practice guideline recommends using NGS to
obtain comprehensive information on mutations in multiple
genes in metastatic tumors.5 Nevertheless, NGS technologies are
underused in developed and predominantly in developing coun-
tries because of, for example, the high cost of establishing and
maintaining NGS facilities, lack of skilled staff, lack of educational
programs, and lack of a regulatory framework. Although the cost
of sequencing has decreased in recent years, other challenges for
the adoption of NGS into clinical practice still persist.40,41 More
funds for genomic research, centralized NGS facilities at the
regional or national level, training programs, and international
collaborations may enhance the application of NGS technologies
worldwide.42,43
Second, although the evidence was already available in 2013
that KRAS and NRAS status should be wild-type before treatment
with anti-EGFR agents (panitumumab),44,45 the recommenda-
tions on NRAS mutation status are reported only in guidelines
124 VALUE IN HEALTH JANUARY 2020published from 2015.5,10,11,30 Before 2015, NRAS was not
reported among biomarkers for the treatment of advanced
CRC46-49 and was not recommended for inclusion in clinical
routine.50 Given the above, studies published before 2013
cannot be expected to have taken NRAS mutation status into
account in their economic models. Nevertheless, clinical
guidelines should be updated in a timely fashion when relevant
new evidence becomes available.
Third, two studies25,27 inappropriately used BRAF genetic
testing to guide the therapy of mCRC patients with cetuximab.
BRAF testing is recommended for prognostic assessment or se-
lection for clinical trials10,11 but not for routine testing. Never-
theless, clinical trials of BRAF-targeted therapies (eg, encorafenib,
binimetinib) are currently under investigation, suggesting new
treatment strategies for BRAF-mutant CRC that could justify BRAF
routine testing.51,52 Economic evaluations should adhere strictly to
guideline recommendations when selecting genes for assessment
in mCRC patients. This would refine patient selection for the
economic models and therefore could lead to more accurate
results.
Finally, economic evaluations were not cited in recent guide-
lines.5,10,11 Economic evaluations of available treatment options
are a valuable support to clinical practice, because financial out-
comes of healthcare services cannot be disregarded, especially in
times of economic contraction. They facilitate the awareness of
healthcare costs and thus should be considered in clinical
guidelines.
The basic assumptions used to build the various economic
models we reviewed here showed both differences and
similarities. For instance, the sensitivity and specificity of KRAS
and BRAF genetic testing, derived from literature studies, were
included in only 2 economic evaluations.26,27 The values reported
were similar in the 2 studies, but Vijayaraghavan et al26 varied the
sensitivity and specificity of the KRAS test from 75% to 100% for the
cetuximab-only strategy. The study demonstrated that evenwith a
lower specificity of KRAS testing, not performing the test before
chemotherapy was still not cost-effective. It should be kept in
mind that sensitivity and specificity values for RAS genetic testing
are surrounded by uncertainty. A recent clinical guideline reported
assay sensitivity for KRAS mutation testing in the range of 84% to
100% across different testing methods, with Sanger sequencing at
the lower end of the range. Specificity ranged from 98% to 100% for
most assays, but some studies have reported lower values.5
Specificity and sensitivity values for RAS testing should be
investigated in future economic evaluations to enhance the
understanding of their influence on outcomes. Another
inconsistency across the studies was the inclusion of adverse
events. Most studies25-27,29 did not consider these events at all.
Saito et al24 did not include adverse events associated with
panitumumab treatment because their rates are extremely low
and the 2 parameters reported (skin toxicity, hypertension) did
not affect the model. The study by Behl et al25 confirmed these
conclusions. In contrast, the Ontario Ministry of Health28
incorporated adverse events with associated costs for all
therapeutic regimens reported. The highest cost was associated
with neutropenia ($4645), which occurred in more than 20% of
patients treated with combination therapy, the preferred
cost-effective option in Ontario. Adverse events, which
particularly relate to the toxicity of biological agents, should be
routinely included in economic evaluations for a comprehensive
assessment of the available therapeutic options and for a more
accurate cost-effectiveness analysis.
The included studies present other methodological limitations
that may have biased the results. The perspectives adopted in all
studies are from the point of view of the payer or provider. Byexcluding the societal level, the studies do not account for all ef-
fects on patients, their families, and the public. Furthermore, price
adjustments for inflation or currency conversion were not given in
2 studies26,28; of the 4 studies that performed a CUA, methods to
value benefits were not stated in 2 of them28,29; OS and PFS were
reported differently across the studies, limiting direct compari-
sons of the estimates, and PFS outcomes were not provided for the
different strategies in one study.25 The analysis covers a limited
number of countries, and none of the studies discussed the
applicability of their outcomes to other settings.24-29 Some clinical
and utility data were not available for the specific settings of the
studies and were derived from other countries24,27,29 or not
included in the model.26 The source of funding (Table 1) was not
declared in one study,24 whereas Roche, a leading provider of
genetic tests, funded 2 studies.26,29 The Philips checklist21 high-
lighted other sources of bias, especially in the data section.
Although data for most parameters were derived from trials,
systematic methods were not used to identify the most appro-
priate data.24,26,29 None of the studies assessed the quality of the
data or used meta-analysis to synthesize treatment effects. All 4
types of uncertainty were not considered. There is a need for a
rigorous methodological approach and more transparency in
reporting modeling studies. These issues should be addressed in
future studies for the appropriate development of economic
models.
The present review has some limitations that should be
pointed out. The review included only 6 studies on RAS mutation
analysis in mCRC patients. Nevertheless, the studies are of good
quality, as underlined by the QHES assessment. The detailed
therapeutic regimens and model parameters varied among
studies, contributing to the heterogeneity of the results; thus, a
meta-analysis was not performed. Consequently, publication bias
could not be investigated; this is also due to the lack of a registry
of model-based economic evaluations reporting on previous
studies or those currently underway.53Conclusions
The treatment pattern for mCRC is rapidly shifting to a more
personalized approach, which is essential if the use of inappro-
priate therapy, with its associated undesirable effects and high
costs, is to be avoided. Although the strategies involving RAS
testing and the use of monoclonal antibodies are expensive, the
benefit is high because RAS mutational status is a negative pre-
dictive biomarker for anti-EGFR therapies in mCRC patients. In
recent years, newer targeted therapies with better outcomes for
mCRC patients have been approved (eg, trifluridine-tipiracil,
pembrolizumab),54 but their application can increase treatment
costs substantially; thus, the cost of targeted therapies needs to be
significantly reduced for their integration into routine clinical
practice.55,56
The economic evaluations, although of good quality, do not
fully adhere to international recommendations regarding the
assessment of mutational status before therapy with biological
agents. Future economic assessments should consider NRAS mu-
tation analysis and other parameters that reflect the real world,
such as toxicity of biological agents, the sensitivity and specificity
of genetic tests, and ethical, legal, and social issues relating to
genome sequencing. International guidelines should consider the
economic aspects of treatment strategies because the financial
outcomes of healthcare services should not be disregarded.
Adherence to guidelines for modeling studies and to clinical
guidelines for the management of mCRC patients could enhance
the accuracy of economic evaluations, which are essential for
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